RadNet’s Strategic Growth and AI Success Justify Buy Rating Despite Concerns
I'm PortAI, I can summarize articles.
Raymond James analyst John Ransom maintains a Buy rating on RadNet (RDNT) stock, citing strategic growth and AI success. Despite concerns, RadNet's consolidation of facilities and effective cost management are highlighted. Imaging center revenue and EBITDA growth are projected at 10% and 11%, respectively. Ransom emphasizes RadNet's AI success in breast cancer detection and expects stock compensation to normalize. B. Riley Securities also reiterates a Buy rating with an $87.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments